About Microbot Medical Inc.
Microbot, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.
TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/.
2. Forward Looking Statements
THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC.
(“MICROBOT”) AND IS NOT FOR PUBLIC DISTRIBUTION. This document has been prepared for informational purposes only and is provided
personally to you. By accepting this document you agree to keep its contents strictly confidential, not to copy any portion of this document and to
return it to Microbot promptly upon its request. This document contains summary information about Microbot, does not purport to be complete,
and no representations or warranties about such information are made by Microbot or its representatives.
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities of Microbot. Any such offer will be made
only pursuant to an effective registration statement or an exemption from registration.
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot. Forward-looking
statements, which involve assumptions and describe Microbot’s intent, belief or current expectations about its business opportunities, prospects,
performance and results, are generally identifiable by use of the words “may,” “could,” “should,” “will,” “would,” “expect,” “anticipate,” “plan,”
“potential,” “estimate,” “believe,” “intend,” “project,” “forecast,” the negative of such words and other variations on such words or similar
terminology. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks
and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and
those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and
uncertainties identified in Microbot’s public filings with the Securities and Exchange Commission, such as market risk, liquidity risk, competitive
risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and
assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.
3. The Medical Robotics Market
Becoming
Smaller, Automated,
and More Precise
MIS Expected to Reach
>$50B Market
by 2019
Applies to
Most Surgical
Specialties
Expected
>20% CAGR
through 2023
4. Mazor Robotics and Medtronic Enter Next Phase
of Strategic Partnership; Medtronic to Make a
$40 million Third Tranche Investment in Mazor
Business Wire, August 30, 2017
5. Mazor Robotics and Medtronic Enter Next Phase
of Strategic Partnership; Medtronic to Make a
$40 million Third Tranche Investment in Mazor
Business Wire, August 30, 2017
Johnson & Johnson Announces Formation of
Verb Surgical Inc., in Collaboration with Verily
PR Newswire, December 10, 2015
6. Mazor Robotics and Medtronic Enter Next Phase
of Strategic Partnership; Medtronic to Make a
$40 million Third Tranche Investment in Mazor
Business Wire, August 30, 2017
Johnson & Johnson Announces Formation of
Verb Surgical Inc., in Collaboration with Verily
PR Newswire, December 10, 2015
Zimmer Biomet Acquires Medtech SA,
Joins Surgical Robotics Fray
Med Device Online, July 20, 2016
7. Mazor Robotics and Medtronic Enter Next Phase
of Strategic Partnership; Medtronic to Make a
$40 million Third Tranche Investment in Mazor
Business Wire, August 30, 2017
Johnson & Johnson Announces Formation of
Verb Surgical Inc., in Collaboration with Verily
PR Newswire, December 10, 2015
Zimmer Biomet Acquires Medtech SA,
Joins Surgical Robotics Fray
Med Device Online, July 20, 2016
Globus Medical Announces Acquisition of
Robotics Developer KB Medical
Reuters, August 2, 2017
14. The sale of
STEM assets for
$4 million
Two separate capital
market transactions
totaling over
$13.5 million
Non-dilutive grant of
~$735,000
from the state of Israel
Ministry of Economy
Strengthened Balance Sheet
15. Strengthened Intellectual Property Portfolio
24 patents issued/allowed and an additional 12 patent applications pending worldwide
FAMILY TITLE US PATENT/APP NO. OTHER COUNTRIES
TipCAT
Tip Propelled Device for Motion Through a Passage
US 9,061,118
US 14/746,660 (allowed)
Granted: EP (DE, FR, GB, IT), CA, JP, IN , CN (3 patents)
Inflatable Chamber Device for Motion Through a Passage
US 9,427,143
US 15/218,025
Granted: EP (DE, FR, GB, IT)
Inflatable Balloon Device and Applications
US 8,430,810
US 8,790,246
Pending: EP
Multi-view Imaging System US 8,317,688
Semi-Disposable Endoscope US 8,398,540 Granted: EP (DE, FR, GB)
ViRob
Vibrating Robotic Crawler US 8,294,333
Granted: IL
Pending: IN, CN, EP
Self Cleaning Shunt
US 9,393,389
US 15/187,003
Granted: CN, JP, CA
Pending: EP, IN
Stent for Restenosis Prevention US 9,510,959
Device for Prevention of Shunt Stenosis
US 9,675,748
US 15/592,227
Pending: EP, CA, IL
16. Enter into agreement to acquire novel technology
to enhance existing technology platforms
Bringing unique capabilities to guidewires
being used in almost every surgical space today
Strengthened Lumen Surgery Technology Platforms
17. Strengthened Leadership Team
Martin Madden
• Former Vice President, Research & Development at
Johnson & Johnson for Interventional Vascular, Global
Surgery and Orthopedics Divisions
• Over 30 years of extensive experience in the
development of hundreds of medical projects
P. (Laxmin) Laxminarain
• Former Worldwide President of Codman
Neurosurgery (a Johnson & Johnson company), sold
to Integra Life science for over $1B in 2017
• 30 years’ experience of senior leadership in the USA
and globally
Enhanced the leadership of the Company with proven medical device experts
Notes de l'éditeur
Then JnJ is not competing against other medical device companies, we are really competing against the majority of surgeons who have not yet made this conceptual leap.
And our challenge is to understand how we enable all of these surgeons to provide MIS to their patients.
Then JnJ is not competing against other medical device companies, we are really competing against the majority of surgeons who have not yet made this conceptual leap.
And our challenge is to understand how we enable all of these surgeons to provide MIS to their patients.
Then JnJ is not competing against other medical device companies, we are really competing against the majority of surgeons who have not yet made this conceptual leap.
And our challenge is to understand how we enable all of these surgeons to provide MIS to their patients.
Then JnJ is not competing against other medical device companies, we are really competing against the majority of surgeons who have not yet made this conceptual leap.
And our challenge is to understand how we enable all of these surgeons to provide MIS to their patients.
